Search Results
Mar 22, 2026, 22:18 ET Henlius présente ses résultats pour 2025 : croissance soutenue du chiffre d'affaires et du bénéfice, progression de la validation de l'innovation et des opérations mondiales
Henlius continue de faire progresser son pipeline d'innovations, avec des actifs clés tels que dulpatatug (HLX22, nouvel épitope anti-HER2 mAb) et HLX43 (PD-L1 ADC) qui entrent dans des phases cliniques critiques.Grâce à ses capacités intégrées en matière de R&D, d'opérations cliniques, de réglementation,
More news about: Henlius
Mar 22, 2026, 22:14 ET Henlius gibt Ergebnisse für 2025 bekannt: Anhaltendes Wachstum bei Umsatz und Gewinn, Ausbau der Innovationsvalidierung und der weltweiten Geschäftstätigkeit
gleichzeitig seine Innovationspipeline weiter voran und wichtige Wirkstoffe wie Dulpatatug (HLX22, ein neuartiger Epitop-Anti-HER2-mAb) und HLX43 (PD-L1-ADC) treten nun in entscheidende klinische Phasen ein.Gestützt auf seine integrierten Kompetenzen in den Bereichen Forschung und Entwicklung, klinische
More news about: Henlius
Mar 20, 2026, 09:23 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
Meanwhile, Henlius continues to advance its innovation pipeline, with key assets including dulpatatug (HLX22, novel epitope anti-HER2 mAb) and HLX43 (PD-L1 ADC) entering critical clinical stages.Supported by its integrated capabilities spanning R&D, clinical operations, regulatory, manufacturing,
More news about: Henlius
Mar 20, 2026, 09:03 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
Europe), is the world's first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope
More news about: Henlius
Mar 20, 2026, 09:03 ET 復宏漢霖2025年業績：收入利潤持續雙增長，體系出海加速落地，創新管線進入密集驗證期
5年，復宏漢霖持續強化平台化創新體系建設，形成涵蓋下一代IO平台、Hanjugator™ ADC平台、三特性T細胞銜接器及AI驅動的一站式抗體藥物早期研發HAI Club平台在內的多維技術平台。業績期內，HLX37（PD-L1 x VEGF雙抗）、HLX97（KAT6A/B小分子抑制劑）、HLX3901（DLL3 x DLL3 x CD3 x CD28四抗TCE）、HLX316（B7-H3唾液酸酶融合蛋白）等分子獲得新藥臨床試驗批准。同時，公司持續推進多款潛力候選分子研發，包括HLX3902（STEAP1
More news about: 復宏漢霖
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
ATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an "IO + ADC" dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of IO therapies. By simultaneously blocking B7-H3- and PD-L1-mediated immunosuppressive
More news about: Antengene Corporation Limited
Mar 19, 2026, 09:00 ET ImmunoBrain Presents Clinical Data for First Immune Checkpoint Therapy Approach in Alzheimer's Disease at AD/PD™ 2026
repair process. I look forward to seeing additional clinical data for this program." IBC-Ab002 is a proprietary anti-PD-L1 monoclonal antibody engineered for intermittent PD-1/PD-L1 pathway blockade to reinvigorate adaptive immunity and recruit reparative immune cells that can help reduce local brain
More news about: ImmunoBrain Checkpoint Inc.
Mar 18, 2026, 20:00 ET SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
& efficacy of iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based antibody-drug conjugate (ADC) in combination with serplulimab (an anti-PD1 antibody), in treatment-naive patients with Extensive stage Small Cell Lung Cancer (ES-SCLC) will be presented REDMOND,
More news about: SystImmune, Inc.
Mar 18, 2026, 14:58 ET Cyber Insurance Market to Reach USD 118.97 Billion by 2032 Amid Rising Ransomware Risk, Regulatory Pressure, and AI-Driven Underwriting Innovation - Credence Research
proactive risk management and multiple specialized coverage options. Insurance Journal said the suite included enhanced Cyber Ctrl cover, Cyber Ctrl PD+ with physical damage protection, Professional Ctrl combining cyber with technology, media, and E&O coverage, and sector-specific endorsements for
More news about: Credence Research Inc.
Mar 18, 2026, 10:44 ET /C O R R E C T I O N -- NeuroSense/
important scientific foundation as we advance toward the PARAGON Phase 3 study. I look forward to sharing these results with the scientific community at AD/PD 2026 and to contributing, together with fellow investigators, to the next stage of clinical development as we work to advance meaningful therapeutic
More news about: NeuroSense
Mar 18, 2026, 09:14 ET Phanes Therapeutics to Present Three Clinical Posters at AACR 2026
entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, pembrolizumab.The US multi-center Phase 1/2 clinical trial of spevatamig (NCT05482893) is evaluating the safety, tolerability, pharmacokinetics,
More news about: Phanes Therapeutics, Inc.
Mar 18, 2026, 09:00 ET Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases
(ANPD001) in PD patients aged 50–70.The study's primary aim is to assess safety and tolerability of bilateral intracranial administration of autologous iPSC DANPCs into the post-commissural putamen.The study's secondary aim is to evaluate change in clinician- and patient-reported PD-specific
More news about: Aspen Neuroscience, Inc.
Mar 18, 2026, 08:00 ET Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
NCT05848739) is a first-in-human, open-label, Phase 1/2 dose escalation and expansion study designed to determine the safety, tolerability, PK, PD and early efficacy of ST316. The Phase 1 dose escalation portion of the study tested various dose levels of ST316 in patients with selected advanced
More news about: Sapience Therapeutics, Inc.
Mar 18, 2026, 08:00 ET MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks. The study will assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and
More news about: MetaVia Inc.
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
IFNα INDUKINE™ molecule, and is currently in Phase 1 development for the investigational use in solid tumors as monotherapy and in combination with a PD-1 inhibitor. JZP898 is an engineered IFN⍺2b cytokine pro-drug that is activated specifically within the tumor microenvironment where it can stimulate
More news about: Jazz Pharmaceuticals plc
Mar 18, 2026, 02:34 ET Para Light Shatters Thermal Limits with ThermaFlat™ SiC MOSFETs Featuring Industry-Leading RDS(on) Stability
nearly constant resistance throughout this entire temperature span, paired with minimal switching loss. Even more remarkable is the high-voltage offering PD035S120ANC (1200V), which limits RDS(on) increase to a mere 26% over the same temperature range—a breakthrough performance that
More news about: Para Light Electronics Co., Ltd.
Mar 17, 2026, 20:30 ET Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
Details of the Poster Presentation:ATG-125 (B7-H3 x PD-L1 bispecific ADC)Title: ATG-125, a novel B7H3 x PD-L1 bispecific antibody-drug conjugate, demonstrates potent antitumor efficacy by dual targeting of immune evasion
More news about: Antengene Corporation Limited
Mar 17, 2026, 19:09 ET MediaTek Develops Active Optical Cable Technology with Microsoft Research to Deliver Significant Improvements in Data Center Efficiency
latency overhead typically associated with multi-chip interconnects.Heterogeneous Integration: The MicroLED array and Photodetector (PD) array are directly bonded onto this monolithic CMOS chip. This advanced co-packaging approach removes the physical constraints of traditional wire-bonding
More news about: MediaTek Inc.
Mar 17, 2026, 17:00 ET GV20 Therapeutics Announces Late-Breaking Oral Presentation of GV20-0251 Translational Findings at the AACR Annual Meeting 2026
studies show that anti-IGSF8 antibodies enhance NK cell cytotoxicity, dendritic cell antigen presentation, and T cell activation, both alone and with anti-PD1. GV20-0251 advanced from target discovery to IND in three years, marking a paradigm shift in AI-driven antibody drug discovery. GV20-251 is the first
More news about: GV20 Therapeutics
Mar 17, 2026, 16:46 ET Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program
Brenig to present Phase 1 BT-267 data at AD/PD 2026; BT-409 Phase 1 trial underway.The presentation will highlight emerging clinical data evaluating the safety, tolerability, pharmacokinetics
More news about: Brenig Therapeutics Inc
Mar 16, 2026, 13:58 ET New Poll: Voters Back Increased Parkinson's Research Funding, Action on the Herbicide Paraquat as Advocates Convene on Capitol Hill
critical moment. We're proud to bring the voices and stories of the 1.2 million people in the U.S. living with PD to the halls of Congress and call for urgent action to support those living with PD, and beat this disease.""At PMD Alliance, we build all of our initiatives by first listening to community
More news about: The Michael J. Fox Foundation for Parkinson's Research
Mar 16, 2026, 13:57 ET Egret Therapeutics Signs Memorandum of Understanding with Genexine Toward Full Ownership of Lead PD-1 Agonist Asset GX-P1 (EGT-101)
intercepting the PD-1+ monocyte-driven inflammatory cascade responsible for fatal cerebral swelling.About GX-P1 (EGT-101)EGT-101 is a first-in-class PD-L1-hyFc fusion protein designed for single-dose immune modulation following ischemic and traumatic injury. By selectively engaging PD-1 on circulating
More news about: Turret Capital Management
Mar 16, 2026, 04:30 ET Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026
Forum talk: Targets to Therapies "Translational R&D for α-synuclein, LRRK2, and GBA pathologies in PD, LBD and MSASpeakersJamie Eberling (US)Keneth
More news about: H. Lundbeck A/S
Mar 16, 2026, 04:27 ET Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026
Forum talk: Targets to Therapies "Translational R&D for α-synuclein, LRRK2, and GBA pathologies in PD, LBD and MSASpeakersJamie Eberling (US)Keneth
More news about: H. Lundbeck A/S
Mar 13, 2026, 00:35 ET Come Talk to ME Selected for Minneapolis-Saint Paul International Film Festival
Main, 115 SE Main Street, Minneapolis, MN 55414Come Talk To ME follows Parkinson's disease (PD) activist Jackie Hunt Christensen, her husband Paul, and a group of friends with PD as they reflect on the many types of communication that are necessary to allow them to participate fully in
More news about: COME TALK TO ME LLC